<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vibrio vulnificus infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vibrio vulnificus infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vibrio vulnificus infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Glenn Morris, Jr, MD, MPHTM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Vibrio vulnificus
         </em>
         is a gram-negative rod that can cause primary septicemia, wound infection, or diarrheal illness [
         <a href="#rid1">
          1-3
         </a>
         ]. Serious infection due to
         <em>
          V. vulnificus
         </em>
         is most common among individuals with chronic, underlying illnesses
         <strong>
          –
         </strong>
         with particular risks associated with liver disease or hemochromatosis. It is the leading cause of shellfish-associated deaths in the United States.
        </p>
        <p>
         The epidemiology, clinical features, diagnosis, and treatment of
         <em>
          V. vulnificus
         </em>
         infections will be reviewed here.
        </p>
        <p>
         Issues related to cholera (caused by
         <em>
          Vibrio cholerae
         </em>
         ) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2704.html" rel="external">
          "Cholera: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141337.html" rel="external">
          "Cholera: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         Issues related to infection caused by
         <em>
          Vibrio parahaemolyticus
         </em>
         , as well as illnesses associated with other
         <em>
          Vibrio
         </em>
         strains and species, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3127.html" rel="external">
          "Vibrio parahaemolyticus infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3145.html" rel="external">
          "Infections due to non-O1/O139 Vibrio cholerae"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16535.html" rel="external">
          "Minor Vibrio and Vibrio-like species associated with human disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4015313720">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1956823745">
         <span class="h2">
          Geography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Worldwide, Vibrio are found in marine environments, including salt water and brackish water (a mix of salt water and fresh water). Environments where Vibrio
         <em>
          may be found include
         </em>
         <strong>
          river estuaries
         </strong>
         and saltwater marshes/wetlands [
         <a href="#rid4">
          4,5
         </a>
         ]. Under optimal conditions it can be relatively common; in the Chesapeake Bay, it has been reported to account for approximately 8 percent of the total aerobic bacterial population [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         V. vulnificus
         <strong>
          bacteria thrive in warmer waters – especially during the summer and fall (when water temperatures are highest).
         </strong>
         <em>
          V. vulnificus
         </em>
         is rarely detected in winter months, in settings in which water temperatures drop consistently below 20°C (68°F). An association between increased temperatures and case numbers has been observed [
         <a href="#rid7">
          7,8
         </a>
         ]. In addition, extreme weather events, such as coastal floods, hurricanes, and storm surges, can force coastal waters into inland areas, putting people who are exposed to these waters at increased risk for Vibrio wound infections [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         V. vulnificus
         <strong>
         </strong>
         <em>
          are concentrated by
         </em>
         <strong>
          <em>
          </em>
         </strong>
         filter-feeding shellfish; oysters may have
         <em>
          V. vulnificus
         </em>
         counts up to two orders of magnitude greater than those in the surrounding water.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          United States
         </strong>
         – Approximately 150 to 200 V. vulnificus infections are reported to the United States Centers for Disease Control and Prevention (CDC) each year and approximately one in five people die, sometimes within one to two days of becoming ill.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the United States, V. vulnificus infections have been reported most commonly by Gulf Coast states. However, V. vulnificus infections in the Eastern United States increased eightfold between 1988 and 2018, and the northern geographic range of this infection has increased by 48 km per year [
         <a href="#rid10">
          10,11
         </a>
         ]. From July to August 2023, several East Coast states (including Connecticut, New York, and North Carolina) reported severe and fatal V. vulnificus infections, corresponding with increasing sea temperatures [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H730968903">
         <span class="h2">
          Transmission
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consumption of raw or undercooked seafood
         </strong>
         – V. vulnificus may be transmitted via consumption of raw or undercooked seafood (primarily oysters, less commonly other shellfish or fish). More than 90 percent of patients with primary septicemia associated
         <em>
         </em>
         with
         <em>
          V. vulnificus
         </em>
         infection report consumption of raw oysters prior to onset of illness [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contact of an open wound with salt water, brackish water, or raw or undercooked seafood
         </strong>
         – V. vulnificus may be acquired via contamination of an open wound with salt water or brackish water containing the microorganism. Open wounds include those from recent surgery, skin piercing, tattoo, and other cuts or scrapes – including those acquired while handling seafood (such as opening oysters) or in association with recreational water activity (such as swimming or entering, exiting, or launching boats) [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1041637979">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with the following conditions are at increased risk for serious infection with
         <em>
          V. vulnificus
         </em>
         [
         <a href="#rid2">
          2,14,16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcoholic cirrhosis (present in 31 to 43 percent of patients with primary septicemia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underlying liver disease including chronic hepatitis due to alcohol or other causes (24 to 31 percent of patients)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to heavy alcohol use (in the absence of documented liver disease) (12 to 27 percent of patients)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary hemochromatosis (12 percent of patients)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic diseases such as diabetes mellitus, thalassemia, chronic renal failure, rheumatoid arthritis, cancer, lymphoma, or other immunocompromising conditions (7 to 8 percent of patients)
        </p>
        <p>
        </p>
        <p>
         Males (particularly males &gt;40 years of age) appear to be at greater risk for serious infection than females; this may reflect a higher prevalence of liver disease in this group [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3601815584">
         <span class="h1">
          MICROBIOLOGY AND PATHOGENESIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         –
         <strong>
         </strong>
         <em>
          V. vulnificus
         </em>
         exists as a free-living gram-negative rod. Three biotypes of
         <em>
          V. vulnificus
         </em>
         have been recognized. Biotype 1 accounts for almost all human infections. Biotype 2 consists primarily of eel pathogens. Biotype 3 is an apparent hybrid of biotypes 1 and 2 that has been described in tilapia-associated wound infections associated with aquaculture in Israel [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These biotypes correlate (to a reasonable degree) with phylogenetic studies, which have identified five well-supported
         <em>
          V. vulnificus
         </em>
         phylogenetic lineages [
         <a href="#rid21">
          21
         </a>
         ]. Biotype 1 strains are found primarily in lineage 1 (but also lineages 2, 4, and 5); biotype 2 strains in lineage 2; and biotype 3 strains in lineage 3.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The virulence of
         <em>
          V. vulnificus
         </em>
         has been associated with a variety of potential factors; these include production of an anti-phagocytic polysaccharide capsule [
         <a href="#rid22">
          22
         </a>
         ], toxin production [
         <a href="#rid23">
          23,24
         </a>
         ], and iron availability and iron acquisition systems [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Capsule
         </strong>
         –
         <em>
          V. vulnificus
         </em>
         produces a capsular polysaccharide that provides protection against phagocytosis and opsonization [
         <a href="#rid22">
          22
         </a>
         ]. Strains are able to shift between encapsulated forms (opaque colony morphology) and unencapsulated forms (translucent colony morphology). When these strains are taken up by oysters, there is a high rate of shift to the encapsulated phenotype, suggesting that oyster passage selects for the encapsulated, virulent form of the organism [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Anticapsular antibodies are protective, but appear to be type-specific [
         <a href="#rid29">
          29
         </a>
         ]. This is significant since
         <em>
          V. vulnificus
         </em>
         has great diversity in capsular types. In one study of 120 strains, for example, 96 different capsular types ("carbotypes") were identified [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <em>
          V. vulnificus
         </em>
         contains a lipopolysaccharide (LPS); however, in contrast to
         <em>
          Escherichia coli
         </em>
         and other members of the Enterobacteriaceae, the LPS of
         <em>
          V. vulnificus
         </em>
         is not a strong trigger for release of tumor necrosis factor (TNF)-alpha and other shock-related cytokines. However, capsular polysaccharide itself may directly trigger some cytokine responses, contributing to the development of shock [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Toxins
         </strong>
         –
         <em>
          V. vulnificus
         </em>
         produces a variety of extracellular toxins, including the metalloprotease VvpE, the cytolysin/hemolysin VvhA, and the multifunctional autoprocessing repeats-in-toxins (MARTX) toxin. While both VvhA and MARTX toxin contribute to virulence, in vivo studies in mice suggest that the MARTX toxin is a major driver for bacterial dissemination from the intestine and subsequent sepsis [
         <a href="#rid24">
          24,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Iron
         </strong>
         – Growth of
         <em>
          V. vulnificus
         </em>
         is dependent in part upon the availability of iron [
         <a href="#rid25">
          25-27
         </a>
         ]. When transferrin iron saturation exceeds 70 percent, growth of the organism is nearly exponential [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The relationship between iron and
         <em>
          V. vulnificus
         </em>
         virulence may account for enhanced susceptibility to serious
         <em>
          V. vulnificus
         </em>
         infections among patients with hemochromatosis [
         <a href="#rid33">
          33,34
         </a>
         ]. However, most patients with serious
         <em>
          V. vulnificus
         </em>
         infection have normal iron and iron saturation levels. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Susceptibility to infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Differentiating strains
         </strong>
         – Certain strain subsets may be more likely to cause human disease; this is in keeping with phylogenetic studies, which demonstrate clustering of human isolates in lineage 1 [
         <a href="#rid21">
          21
         </a>
         ]. However, it has not been possible to identify a single
         <em>
          V. vulnificus
         </em>
         virulence factor present in all clinical isolates [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical manifestations of
         <em>
          V. vulnificus
         </em>
         include primary septicemia (45 to 60 percent of cases), wound infection (30 to 45 percent of cases), and diarrhea (5 to 10 percent of cases) [
         <a href="#rid3">
          3,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Primary septicemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary septicemia due to
         <em>
          V. vulnificus
         </em>
         (ie, septicemia with no clear localizing source such as a wound) is associated with ingestion of raw or undercooked seafood; patients may or may not have antecedent gastrointestinal illness [
         <a href="#rid36">
          36
         </a>
         ]. Patients with primary septicemia nearly always have an underlying comorbidity (often cirrhosis). (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         Onset of hypotension is rapid; approximately one-third of patients with primary septicemia present with shock or become hypotensive within 12 hours of hospital admission [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         .)
        </p>
        <p>
         Acute skin findings usually appear within 24 hours of sepsis onset. These usually involve the lower extremities, are frequently bilateral, and manifest as severe cellulitis with fluid-filled bullae, which then may become hemorrhagic  (
         <a class="graphic graphic_picture graphicRef55001" href="/z/d/graphic/55001.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef63423" href="/z/d/graphic/63423.html" rel="external">
          picture 2
         </a>
         ). The lesions may progress rapidly to necrotic ulceration, gangrene, and necrotizing fasciitis with myonecrosis. (See
         <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">
          "Necrotizing soft tissue infections", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Thrombocytopenia is common, and often there is evidence of disseminated intravascular coagulation. Complications such as gastrointestinal bleeding can occur.
        </p>
        <p>
         Persons who survive acute shock often require prolonged hospitalization. While there may be recovery from
         <em>
          V. vulnificus
         </em>
         infection, there may be ongoing morbidity due to associated multiorgan system failure.
        </p>
        <p>
         Primary septicemia due to
         <em>
          V. vulnificus
         </em>
         is a serious illness with a high mortality rate. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2605680081">
         <span class="h2">
          Wound infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         V. vulnificus may be transmitted via contact of an open wound with salt water or brackish water containing the microorganism. (See
         <a class="local">
          'Transmission'
         </a>
         above.)
        </p>
        <p>
         Signs and symptoms of
         <em>
          V. vulnificus
         </em>
         wound infection range from mild cellulitis (skin redness, warmth, swelling, and pain) to severe infection resulting in muscle involvement and widespread tissue destruction. Manifestations may include swelling, ecchymosis, blister formation, ulceration, hemorrhagic bullae, and abscess. They may progress rapidly to necrotizing fasciitis and myonecrosis, especially among individuals with an underlying comorbidity. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">
          "Necrotizing soft tissue infections", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         These manifestations are localized, at least initially, to the area of the initial wound and therefore may be differentiated from the bilateral lower extremity pattern of skin findings in the presentation of primary sepsis (see
         <a class="local">
          'Primary septicemia'
         </a>
         above). Patients with primary wound infection are at high risk for development of bacteremia, sepsis, and limb loss.
        </p>
        <p class="headingAnchor" id="H3587713798">
         <span class="h2">
          Diarrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are reports of isolation of
         <em>
          V. vulnificus
         </em>
         from patients with mild to moderate diarrhea, frequently in association with a history of seafood consumption. The relative importance of
         <em>
          V. vulnificus
         </em>
         as a cause of isolated diarrheal illness is uncertain, and cases, when identified, tend to be mild and self-limited [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3376569771">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H3711666585">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         V. vulnificus
         <strong>
         </strong>
         <em>
          infection should be suspected
         </em>
         <strong>
          in the following circumstances, particularly in the context of relevant risk factors
         </strong>
         (see
         <a class="local">
          'Risk factors'
         </a>
         above)
         <strong>
          :
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Septic shock in the context of characteristic bullous skin lesions  (
         <a class="graphic graphic_picture graphicRef55001" href="/z/d/graphic/55001.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef63423" href="/z/d/graphic/63423.html" rel="external">
          picture 2
         </a>
         ) and a history of raw oyster consumption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Wound
         </strong>
         infection associated with contact with salt or brackish water during warm summer months, in an area where water temperatures exceed 20°C and
         <em>
          V. vulnificus
         </em>
         is present in the environment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H196364994">
         <span class="h2">
          History and physical examination
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History – The history should include asking about relevant epidemiologic exposures, including (see
         <a class="local">
          'Transmission'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Contact of an open wound to salt or brackish water
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consumption of raw or undercooked seafood (primarily oysters, less commonly shellfish or fish)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a detailed past medical history should be obtained, to assess for risk factors associated with severe infection. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination – Patients should be evaluated for clinical manifestations described above, including a careful skin and soft tissue examination. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Obtaining diagnostic specimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following specimens should be obtained:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood cultures (for patients with signs of sepsis, hemorrhagic bullae, and/or clinical findings suggestive of an infected wound associated with seawater exposure)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Culture of hemorrhagic bullae (if present)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wound culture (for patients with wound infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stool culture or culture-independent stool testing (for patients with diarrhea in addition to other manifestations suggestive of
         <em>
          V. vulnificus
         </em>
         infection)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1869017312">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of
         <em>
          V. vulnificus
         </em>
         infection is established by culture or molecular identification systems.
        </p>
        <p>
         <em>
          V. vulnificus
         </em>
         grows readily in standard blood culture media or on nonselective media (such as blood agar) routinely used for wound cultures; identification and speciation of the organism is possible via any standard, commercially available microbiology identification system.
        </p>
        <p>
         Identification of
         <em>
          V. vulnificus
         </em>
         in stool is generally done via molecular identification systems; depending on the system used, it may or may not be possible to identify
         <em>
          Vibrios
         </em>
         to the species level. Microbiologic isolation from stool requires use of a specific selective culture media (thiosulfate citrate bile-salts sucrose [TCBS]) on which the organism produces characteristic blue-green colonies. For these reasons, the laboratory should be notified
         <em>
          V. vulnificus
         </em>
         infection is suspected.
        </p>
        <p class="bulletIndent1">
         If
         <em>
          V. vulnificus
         </em>
         is detected by an culture-independent tests (such as a stool multiplex panel) specimens should be set up for reflex culture to obtain antimicrobial susceptibility data.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3803400727">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sepsis – Sepsis may be caused by a broad array of pathogens. (See
         <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">
          "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Soft tissue infection associated with water exposure – Soft tissue infection due to a broad array of organisms can occur in patients with traumatic injury associated with water exposure  (
         <a class="graphic graphic_table graphicRef75469" href="/z/d/graphic/75469.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7646.html" rel="external">
          "Soft tissue infections following water exposure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bullous lesions – Bullous lesions may be observed in other conditions including pemphigus, pemphigoid, Steven-Johnson syndrome, toxic epidermal necrosis, and drug reaction. (See
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Necrotizing soft tissue infection – Necrotizing soft tissue infection may be caused by other microorganisms in addition to
         <em>
          V. vulnificus
         </em>
         ; these include group A
         <em>
          Streptococcus
         </em>
         ,
         <em>
          Staphylococcus
         </em>
         <em>
          aureus
         </em>
         ,
         <em>
          Aeromonas
         </em>
         ,
         <em>
          Pseudomonas
         </em>
         , and
         <em>
          Clostridium perfringens
         </em>
         (
         <a class="graphic graphic_table graphicRef116305" href="/z/d/graphic/116305.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">
          "Necrotizing soft tissue infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea – A broad array of bacteria, viruses, and parasites may be implicated in acute diarrheal illness. (See
         <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">
          "Approach to the adult with acute diarrhea in resource-abundant settings"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">
          "Diagnostic approach to diarrhea in children in resource-abundant settings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2685163672">
         <span class="h2">
          Severe infection
         </span>
        </p>
        <p class="headingAnchor" id="H3797234790">
         <span class="h3">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical approach should be guided by the clinical presentation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with sepsis that is known or suspected to be due to
         <em>
          V. vulnificus
         </em>
         (see
         <a class="local">
          'Clinical suspicion'
         </a>
         above) require prompt initiation of antibiotic therapy with activity against
         <em>
          V. vulnificus
         </em>
         , in addition to supportive care in an intensive care unit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with severe soft tissue infection that is known or suspected to be due to
         <em>
          V. vulnificus
         </em>
         require prompt initiation of antibiotic therapy with activity against
         <em>
          V. vulnificus
         </em>
         , in addition to evaluation for immediate surgical debridement.
        </p>
        <p>
        </p>
        <p>
         In one case series including 62 patients with
         <em>
          V. vulnificus
         </em>
         infection (38 with primary septicemia and 17 with wound infection), mortality was lowest for patients who received antibiotics within the first 24 hours after illness onset compared with those treated 24 to 48 hours later or &gt;72 hours later (33, 53, and 100 percent, respectively) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2195800276">
         <span class="h3">
          Antibiotic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3216685007">
         <span class="h4">
          Selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with primary septicemia or severe wound infection, we treat with combination antibiotic therapy as follows; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef143005" href="/z/d/graphic/143005.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third-generation cephalosporin (eg,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         , or
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         ).
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          Cefepime
         </a>
         may provide adequate coverage but clinical data for this newer agent are limited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PLUS
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         or
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ). A fluoroquinolone (
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ) may be used as an alternative for patients who are not able to tolerate tetracyclines; we prefer ciprofloxacin given limited clinical data for other fluoroquinolones [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Antibiotic selection should be tailored to susceptibility data, when available. In particular, treatment may need to be adjusted for strains with decreased susceptibility to certain third generation cephalosporins.
        </p>
        <p>
         Other antibiotic agents with activity against
         <em>
          V. vulnificus
         </em>
         include carbapenems,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         , aminoglycosides, and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         .
         <em>
          Vibrio
         </em>
         spp tend to respond poorly to treatment with penicillins and first-generation cephalosporins, regardless of susceptibility test results.
        </p>
        <p>
         Use of combination therapy is supported by retrospective trials, case reports, and animal data:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study from Korea including 218 patients with primary septicemia due to
         <em>
          V. vulnificus
         </em>
         , 30-day survival rates following treatment with a third-generation cephalosporin plus
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or a third-generation cephalosporin plus
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         were comparable (54 versus 38 percent) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study from Taiwan including 89 patients with necrotizing fasciitis due to
         <em>
          V. vulnificus
         </em>
         who underwent prompt surgical debridement, the case fatality was lower among those treated with combination therapy (either a third-generation cephalosporin plus
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , or a fluoroquinolone [with or without minocycline]) compared with those who received monotherapy with a third generation cephalosporin (14, 14, and 61 percent, respectively) [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a case report of a child in Taiwan with necrotizing fasciitis due to
         <em>
          V. vulnificus
         </em>
         who was not responding clinically to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , combination treatment with
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         and cefpirome was efficacious as "salvage" therapy [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In vitro and in vivo studies in mice have demonstrated an apparent synergism between
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         for treatment of serious
         <em>
          V. vulnificus
         </em>
         infection [
         <a href="#rid44">
          44
         </a>
         ]. Mouse studies have also highlighted the efficacy of combination therapy with
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         or
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ], cefotaxime plus ciprofloxacin [
         <a href="#rid46">
          46
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         plus cefotaxime [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1369262481">
         <span class="h4">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat for a duration of at least two weeks, given the potential seriousness of the infection and that most patients have underlying chronic conditions. Beyond that, treatment should be tailored to individual patient circumstances. For patients who are responding well clinically, completion of treatment with an oral
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         or fluroquinolone may be reasonable.
        </p>
        <p class="headingAnchor" id="H2735724557">
         <span class="h3">
          Surgical debridement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with serious wound infection require prompt evaluation regarding need for surgical debridement. Skin abscesses should be drained. Severe cases might require aggressive debridement, fasciotomy, or amputation of the infected limb. (See
         <a class="medical medical_review" href="/z/d/html/108059.html" rel="external">
          "Surgical management of necrotizing soft tissue infections"
         </a>
         .)
        </p>
        <p>
         In one series including 121 patients in Taiwan with necrotizing fasciitis due to
         <em>
          V. vulnificus
         </em>
         , the mean time between admission and surgery was shorter among survivors than nonsurvivors (14.1 versus 25.7 hours) [
         <a href="#rid48">
          48
         </a>
         ]. In another study including 423
         <em>
          V. vulnificus
         </em>
         wound infections, 10 percent of patients required amputation [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3896366536">
         <span class="h2">
          Mild infection
         </span>
        </p>
        <p class="headingAnchor" id="H288328989">
         <span class="h3">
          Wound infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment of mild wound infection should be guided by whether risk factors for severe disease are present. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presence of risk factors for severe disease
         </strong>
         – For patients with mild wound infection in the presence of risk factors for severe disease, treatment with combination antibiotic therapy including a third-generation cephalosporin plus a
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (as for severe infection) is appropriate, at least until the infection appears to be resolving and there is minimal risk of associated bacteremia and sepsis. (See
         <a class="local">
          'Severe infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Absence of risk factors for severe disease
         </strong>
         – For patients with mild wound infection in the absence of risk factors for severe disease, management consists of local wound care and oral antibiotic therapy with a
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         or tetracycline)  (
         <a class="graphic graphic_table graphicRef143005" href="/z/d/graphic/143005.html" rel="external">
          table 3
         </a>
         ). A fluoroquinolone may be used an alternative for patients who are not able to tolerate tetracyclines; we prefer
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         given limited clinical data for other fluoroquinolones.
        </p>
        <p>
        </p>
        <p>
         Antibiotic selection should be tailored to susceptibility data, when available.
        </p>
        <p>
         The duration of antibiotic therapy should be guided by the clinical response to treatment; five to seven days is generally sufficient.
        </p>
        <p class="headingAnchor" id="H3864922535">
         <span class="h3">
          Diarrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with isolated mild to moderate diarrhea, symptoms are generally self-limited. Treatment should focus on volume repletion in the absence of antibiotic therapy.
        </p>
        <p class="headingAnchor" id="H1002624428">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          V. vulnificus
         </em>
         infection is a serious illness with a high mortality rate. The case-fatality rate is 50 percent for primary septicemia and approximately 15 percent for wound infection [
         <a href="#rid3">
          3
         </a>
         ]. Among patients who are hypotensive when they present for medical care, a case fatality rate &gt;90 percent has been reported [
         <a href="#rid2">
          2,14,16,49
         </a>
         ]. Advanced liver disease with model for end-stage liver disease (MELD) score &gt;20 has also been associated with high mortality (64-fold increased odds of death) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regarding wounds and cuts:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals (particularly those with increased susceptibility to
         <em>
          V. vulnificus
         </em>
         infection) who have open wounds should avoid situations in which wound exposure to salt or brackish water during warm summer or fall months are likely to occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For high-risk individuals with an open wound that could come in contact with salt or brackish water during warm summer or fall months, the wound should be covered completely with a waterproof bandage.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any open wounds or cuts that come into contact with salt or brackish water should be washed thoroughly with soap and clean, running water.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regarding seafood handling and consumption:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use gloves or wash hands after handling raw shellfish.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals (particularly those with increased susceptibility to
         <em>
          V. vulnificus
         </em>
         infection) should avoid eating raw or undercooked shellfish, particularly oysters, during warm summer or fall months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Post-harvest treatment of raw oysters (such as freezing or mild heat treatment) can reduce counts of
         <em>
          V. vulnificus
         </em>
         and other
         <em>
          Vibrio
         </em>
         species, potentially reducing disease risk [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3115889">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         –
         <em>
          Vibrio vulnificus
         </em>
         is a gram-negative rod that can cause primary septicemia, wound infection, or diarrheal illness. Serious infection occurs most commonly among individuals with underlying comorbidities. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Geography
         </strong>
         –
         <em>
          Vibrio vulnificus
         </em>
         can be relatively common in marine environments, including salt water and brackish water (a mix of salt water and fresh water).
         <em>
         </em>
         V. vulnificus
         <em>
         </em>
         <strong>
          bacteria thrive in warmer waters, and the geographic range is expanding with rising sea temperatures.
         </strong>
         <em>
          The organisms
         </em>
         <em>
          are concentrated by
         </em>
         filter-feeding shellfish (such as oysters). (See
         <a class="local">
          'Geography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transmission
         </strong>
         – Transmission of
         <em>
          V. vulnificus
         </em>
         infection occurs via the following mechanisms (see
         <a class="local">
          'Transmission'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Consumption of raw or undercooked seafood (primarily oysters, less commonly shellfish or fish)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Contact of an open wound with salt or brackish water
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk factors
         </strong>
         – Factors conferring increased risk for serious infection include (see
         <a class="local">
          'Risk factors'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alcoholic cirrhosis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Underlying liver disease including chronic hepatitis due to alcohol or other causes
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Moderate to heavy alcohol use (in the absence of documented liver disease)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hereditary hemochromatosis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chronic diseases such diabetes, thalassemia, renal failure, and immunocompromising conditions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary septicemia
         </strong>
         – Primary septicemia due to
         <em>
          V. vulnificus
         </em>
         (ie, septicemia with no clear localizing source such as a wound) is associated with ingestion of raw or undercooked seafood; patients may or may not have antecedent gastrointestinal illness. Patients with primary septicemia nearly always have an underlying comorbidity (often cirrhosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Onset of hypotension is rapid. Acute skin findings usually appear within 24 hours of sepsis onset. These usually involve the lower extremities, are frequently bilateral, and manifest as severe cellulitis with fluid-filled bullae, which then may become hemorrhagic  (
         <a class="graphic graphic_picture graphicRef55001" href="/z/d/graphic/55001.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef63423" href="/z/d/graphic/63423.html" rel="external">
          picture 2
         </a>
         ). The lesions may progress rapidly to necrotic ulceration, gangrene, and necrotizing fasciitis with myonecrosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Wound infection
         </strong>
         – Signs and symptoms of wound infection range from mild cellulitis (skin redness, warmth, swelling, and pain) to severe infection resulting in muscle involvement and widespread tissue destruction. Manifestations may include swelling, ecchymosis, blister formation, ulceration, hemorrhagic bullae, and abscess. These may progress rapidly to necrotizing fasciitis and myonecrosis, especially among individuals with an underlying comorbidity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diarrhea
         </strong>
         –
         <em>
          V. vulnificus
         </em>
         has been associated with isolated cases of mild to moderate self-limited diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical suspicion
         </strong>
         – V. vulnificus
         <strong>
         </strong>
         <em>
          infection should be suspected
         </em>
         <strong>
          in the following circumstances, particularly in the context of relevant risk factors
         </strong>
         (See
         <a class="local">
          'Clinical suspicion'
         </a>
         above.)
         <strong>
          :
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Septic shock in the context of characteristic bullous skin lesions and a history of raw oyster consumption.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Wound
         </strong>
         infection associated with contact with salt or brackish water during warm summer months, in an area where water temperatures exceed 20°C and
         <em>
          V. vulnificus
         </em>
         is known to be present in the environment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Obtaining diagnostic specimens
         </strong>
         – The following specimens should be obtained (see
         <a class="local">
          'Obtaining diagnostic specimens'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Blood cultures (for patients with fever, hemorrhagic bullae, or signs of sepsis)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Culture of hemorrhagic bullae (if present)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Wound culture (for patients with wound infection)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Stool samples for culture or analysis by culture-independent tests (for patients with diarrhea in addition to other manifestations suggestive of
         <em>
          V. vulnificus
         </em>
         infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of severe infection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical approach
         </strong>
         (see
         <a class="local">
          'Clinical approach'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with sepsis that is known or suspected to be due to
         <em>
          V. vulnificus
         </em>
         require prompt initiation of antibiotic therapy with activity against
         <em>
          V. vulnificus
         </em>
         , in addition to supportive care in an intensive care unit.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with severe soft tissue infection that is known or suspected to be due to
         <em>
          V. vulnificus
         </em>
         require prompt initiation of antibiotic therapy with activity against
         <em>
          V. vulnificus
         </em>
         , in addition to evaluation for immediate surgical debridement.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotic therapy
         </strong>
         – For patients with primary septicemia or severe wound infection, we suggest treatment with combination antibiotic therapy including a third-generation cephalosporin plus a
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (
         <a class="graphic graphic_table graphicRef143005" href="/z/d/graphic/143005.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We treat for at least two weeks duration, tailored to individual patient circumstances. For patients who are responding well clinically, completion of treatment with an oral tetracycline or fluroquinolone may be reasonable. (See
         <a class="local">
          'Antibiotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of mild infection
         </strong>
         (See
         <a class="local">
          'Mild infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Wound infection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Presence of risk factors for severe disease
         </strong>
         – For patients with mild wound infection in the presence of risk factors for severe disease, we suggest initial treatment with combination antibiotic therapy including a third-generation cephalosporin plus a
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (as for severe infection)  (
         <a class="graphic graphic_table graphicRef143005" href="/z/d/graphic/143005.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), at least until the infection appears to be resolving and there is minimal risk of associated bacteremia and sepsis.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Absence of risk factors for severe disease
         </strong>
         – For patients with mild wound infection in the absence of risk factors for severe disease, management consists of local wound care and oral antibiotic therapy; we suggest treatment with a
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (
         <a class="graphic graphic_table graphicRef143005" href="/z/d/graphic/143005.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A fluoroquinolone may be used as an alternative for patients who are not able to tolerate tetracyclines; we prefer
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         given limited clinical data for other fluoroquinolones.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Antibiotic selection should be tailored to susceptibility data, when available. The duration of antibiotic therapy should be guided by the clinical response to treatment; five to seven days is generally sufficient.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diarrhea
         </strong>
         – For patients with isolated mild to moderate diarrhea, symptoms are generally self-limited. Treatment should focus on volume repletion in the absence of antibiotic therapy.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Morris JG Jr, Black RE. Cholera and other vibrioses in the United States. N Engl J Med 1985; 312:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blake PA, Merson MH, Weaver RE, et al. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 1979; 300:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels NA. Vibrio vulnificus oysters: pearls and perils. Clin Infect Dis 2011; 52:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigro OD, James-Davis LI, De Carlo EH, et al. Variable Freshwater Influences on the Abundance of Vibrio vulnificus in a Tropical Urban Estuary. Appl Environ Microbiol 2022; 88:e0188421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffitt KJ, Grimes DJ. Abundance and distribution of Vibrio cholerae, V. parahaemolyticus, and V. vulnificus following a major freshwater intrusion into the Mississippi Sound. Microb Ecol 2013; 65:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright AC, Hill RT, Johnson JA, et al. Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol 1996; 62:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brehm TT, Berneking L, Sena Martins M, et al. Heatwave-associated Vibrio infections in Germany, 2018 and 2019. Euro Surveill 2021; 26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim J, Chun BC. Effect of Seawater Temperature Increase on the Occurrence of Coastal Vibrio vulnificus Cases: Korean National Surveillance Data from 2003 to 2016. Int J Environ Res Public Health 2021; 18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sodders N, Stockdale K, Baker K, et al. Notes from the Field: Vibriosis Cases Associated with Flood Waters During and After Hurricane Ian - Florida, September-October 2022. MMWR Morb Mortal Wkly Rep 2023; 72:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archer EJ, Baker-Austin C, Osborn TJ, et al. Climate warming and increasing Vibrio vulnificus infections in North America. Sci Rep 2023; 13:3893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King M, Rose L, Fraimow H, et al. Vibrio vulnificus Infections From a Previously Nonendemic Area. Ann Intern Med 2019; 171:520.
          </a>
         </li>
         <li class="breakAll">
          Severe Vibrio vulnificus Infections in the United States Associated with Warming Coastal Waters. Centers for Disease Control and Prevention, 2023. https://emergency.cdc.gov/han/2023/han00497.asp (Accessed on September 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones MK, Oliver JD. Vibrio vulnificus: disease and pathogenesis. Infect Immun 2009; 77:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis 2008; 46:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoder JS, Hlavsa MC, Craun GF, et al. Surveillance for waterborne disease and outbreaks associated with recreational water use and other aquatic facility-associated health events--United States, 2005-2006. MMWR Surveill Summ 2008; 57:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tacket CO, Brenner F, Blake PA. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis 1984; 149:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SH, Chung BH, Lee WC. Retrospective analysis of epidemiological aspects of Vibrio vulnificus infections in Korea in 2001-2010. Jpn J Infect Dis 2013; 66:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisharat N, Cohen DI, Harding RM, et al. Hybrid Vibrio vulnificus. Emerg Infect Dis 2005; 11:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisharat N, Agmon V, Finkelstein R, et al. Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group. Lancet 1999; 354:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broza YY, Danin-Poleg Y, Lerner L, et al. Epidemiologic study of Vibrio vulnificus infections by using variable number tandem repeats. Emerg Infect Dis 2009; 15:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roig FJ, González-Candelas F, Sanjuán E, et al. Phylogeny of Vibrio vulnificus from the Analysis of the Core-Genome: Implications for Intra-Species Taxonomy. Front Microbiol 2017; 8:2613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright AC, Simpson LM, Oliver JD, Morris JG Jr. Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun 1990; 58:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung KJ, Cho EJ, Kim MK, et al. RtxA1-induced expression of the small GTPase Rac2 plays a key role in the pathogenicity of Vibrio vulnificus. J Infect Dis 2010; 201:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker-Austin C, Oliver JD. Vibrio vulnificus: new insights into a deadly opportunistic pathogen. Environ Microbiol 2018; 20:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennt CE, Wright AC, Dutta SK, Morris JG Jr. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis 1991; 164:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim CM, Park RY, Choi MH, et al. Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy. J Infect Dis 2007; 195:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim CM, Park YJ, Shin SH. A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus. J Infect Dis 2007; 196:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava M, Tucker MS, Gulig PA, Wright AC. Phase variation, capsular polysaccharide, pilus and flagella contribute to uptake of Vibrio vulnificus by the Eastern oyster (Crassostrea virginica). Environ Microbiol 2009; 11:1934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devi SJ, Hayat U, Powell JL, Morris JG Jr. Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus. Infect Immun 1996; 64:2220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush CA, Patel P, Gunawardena S, et al. Classification of Vibrio vulnificus strains by the carbohydrate composition of their capsular polysaccharides. Anal Biochem 1997; 250:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell JL, Wright AC, Wasserman SS, et al. Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect Immun 1997; 65:3713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavin HE, Satchell KJF. RRSP and RID Effector Domains Dominate the Virulence Impact of Vibrio vulnificus MARTX Toxin. J Infect Dis 2019; 219:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullen JJ, Spalding PB, Ward CG, Gutteridge JM. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991; 151:1606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerhard GS, Levin KA, Price Goldstein J, et al. Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation. Arch Pathol Lab Med 2001; 125:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kling K, Trinh SA, Leyn SA, et al. Genetic Divergence of Vibrio vulnificus Clinical Isolates with Mild to Severe Outcomes. mBio 2022; 13:e0150022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro RL, Altekruse S, Hutwagner L, et al. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis 1998; 178:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SD, Shon HS, Joh NJ. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J Am Acad Dermatol 1991; 24:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston JM, Becker SF, McFarland LM. Gastroenteritis in patients with stool isolates of Vibrio vulnificus. Am J Med 1986; 80:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klontz KC, Lieb S, Schreiber M, et al. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988; 109:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silva LV, Ossai S, Chigbu P, Parveen S. Antimicrobial and Genetic Profiles of Vibrio vulnificus and Vibrio parahaemolyticus Isolated From the Maryland Coastal Bays, United States. Front Microbiol 2021; 12:676249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SE, Shin SU, Oh TH, et al. Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis. PLoS Negl Trop Dis 2019; 13:e0007478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SC, Lee YT, Tsai SJ, et al. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period. J Antimicrob Chemother 2012; 67:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YS, Hung MH, Chen CC, et al. Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: Case report in a child. J Microbiol Immunol Infect 2016; 49:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang YC, Ko WC, Wang ST, et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998; 42:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trinh SA, Gavin HE, Satchell KJF. Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang HC, Choi SM, Kim HK, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One 2014; 9:e101118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang HJ, Chen CC, Lai CC, et al. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect 2018; 51:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao WN, Tsai CF, Chang HR, et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg 2013; 206:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu JW, Lee IK, Tang HJ, et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 2006; 166:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang KC, Tsai YH, Huang KC, Lee MS. Model for end-stage liver disease (MELD) score as a predictor and monitor of mortality in patients with Vibrio vulnificus necrotizing skin and soft tissue infections. PLoS Negl Trop Dis 2015; 9:e0003720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depaola A, Jones JL, Noe KE, et al. Survey of postharvest-processed oysters in the United States for levels of Vibrio vulnificus and Vibrio parahaemolyticus. J Food Prot 2009; 72:2110.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3128 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3881668" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cholera and other vibrioses in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/758155" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Disease caused by a marine Vibrio. Clinical characteristics and epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21367733" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Vibrio vulnificus oysters: pearls and perils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35196141" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Variable Freshwater Influences on the Abundance of Vibrio vulnificus in a Tropical Urban Estuary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23494573" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Abundance and distribution of Vibrio cholerae, V. parahaemolyticus, and V. vulnificus following a major freshwater intrusion into the Mississippi Sound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8593075" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Distribution of Vibrio vulnificus in the Chesapeake Bay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34651572" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Heatwave-associated Vibrio infections in Germany, 2018 and 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33922061" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of Seawater Temperature Increase on the Occurrence of Coastal Vibrio vulnificus Cases: Korean National Surveillance Data from 2003 to 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37141149" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Notes from the Field: Vibriosis Cases Associated with Flood Waters During and After Hurricane Ian - Florida, September-October 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36959189" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Climate warming and increasing Vibrio vulnificus infections in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31207614" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Vibrio vulnificus Infections From a Previously Nonendemic Area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31207614" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Vibrio vulnificus Infections From a Previously Nonendemic Area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255188" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Vibrio vulnificus: disease and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18444811" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18784642" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Surveillance for waterborne disease and outbreaks associated with recreational water use and other aquatic facility-associated health events--United States, 2005-2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6725989" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical features and an epidemiological study of Vibrio vulnificus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23883847" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Retrospective analysis of epidemiological aspects of Vibrio vulnificus infections in Korea in 2001-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705319" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hybrid Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543668" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19751592" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidemiologic study of Vibrio vulnificus infections by using variable number tandem repeats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29358930" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Phylogeny of Vibrio vulnificus from the Analysis of the Core-Genome: Implications for Intra-Species Taxonomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2160432" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19919301" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : RtxA1-induced expression of the small GTPase Rac2 plays a key role in the pathogenicity of Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29027375" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Vibrio vulnificus: new insights into a deadly opportunistic pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1940460" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17152012" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18008234" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19689704" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Phase variation, capsular polysaccharide, pilus and flagella contribute to uptake of Vibrio vulnificus by the Eastern oyster (Crassostrea virginica).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8675330" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9245438" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Classification of Vibrio vulnificus strains by the carbohydrate composition of their capsular polysaccharides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9284142" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30289477" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : RRSP and RID Effector Domains Dominate the Virulence Impact of Vibrio vulnificus MARTX Toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1872665" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hemochromatosis, iron and septicemia caused by Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11473471" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36169197" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Genetic Divergence of Vibrio vulnificus Clinical Isolates with Mild to Severe Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9728544" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2061435" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3946453" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Gastroenteritis in patients with stool isolates of Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3260760" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34093499" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antimicrobial and Genetic Profiles of Vibrio vulnificus and Vibrio parahaemolyticus Isolated From the Maryland Coastal Bays, United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31188821" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22117030" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23751766" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: Case report in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624467" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28971862" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24978586" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27260781" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23414632" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060542" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prognostic factors and antibiotics in Vibrio vulnificus septicemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25923115" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Model for end-stage liver disease (MELD) score as a predictor and monitor of mortality in patients with Vibrio vulnificus necrotizing skin and soft tissue infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19833034" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Survey of postharvest-processed oysters in the United States for levels of Vibrio vulnificus and Vibrio parahaemolyticus.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
